Metastatic Colorectal Cancer (CRC) Clinical Trials

11 recruiting

Metastatic Colorectal Cancer (CRC) Trials at a Glance

11 actively recruiting trials for metastatic colorectal cancer (crc) are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Philadelphia, Houston, and Hangzhou. Lead sponsors running metastatic colorectal cancer (crc) studies include The Methodist Hospital Research Institute, Hansoh BioMedical R&D Company, and Fudan University.

Browse metastatic colorectal cancer (crc) trials by phase

Treatments under study

About Metastatic Colorectal Cancer (CRC) Clinical Trials

Looking for clinical trials for Metastatic Colorectal Cancer (CRC)? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Colorectal Cancer (CRC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Colorectal Cancer (CRC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting

Assessing the Efficacy and Safety of ctDNA-driven Selection for Anti-EGFR Retreatment in a Real World Metastatic Colorectal Cancer Patients Cohort (the REalCHALLENGE Study)

Metastatic Colorectal Cancer (CRC)
Niguarda Hospital250 enrolled1 locationNCT07536113
Recruiting
Phase 2

Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)
The Methodist Hospital Research Institute50 enrolled1 locationNCT07042685
Recruiting
Phase 3

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)
Summit Therapeutics600 enrolled54 locationsNCT07228832
Recruiting
Phase 1

Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal Cancer

Metastatic Colorectal Cancer (CRC)
Ying Yuan, MD20 enrolled1 locationNCT07504523
Recruiting
Phase 3

NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)
Shanghai Zhongshan Hospital144 enrolled1 locationNCT07309289
Recruiting
Early Phase 1

Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

Metastatic Colorectal Cancer (CRC)Oxaliplatin Induced Peripheral Neuropathy in Cancer PatientsPeripheral Neuropathy Due to Chemotherapy
Fox Chase Cancer Center30 enrolled1 locationNCT07167446
Recruiting
Phase 2

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)
The Methodist Hospital Research Institute57 enrolled1 locationNCT06887218
Recruiting
Phase 2

Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer

Metastatic Colorectal Cancer (CRC)
Fudan University119 enrolled1 locationNCT06856187
Recruiting
Phase 2Phase 3

Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)

RadiotherapyMetastatic Colorectal Cancer (CRC)Immune Checkpoint Therapy
Sixth Affiliated Hospital, Sun Yat-sen University286 enrolled1 locationNCT06958419
Recruiting
Phase 1Phase 2

Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer

Metastatic Colorectal Cancer (CRC)Recurrent Colorectal Cancer
STCube, Inc.52 enrolled5 locationsNCT06873763
Recruiting
Phase 1

ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (CRC)
Hansoh BioMedical R&D Company560 enrolled1 locationNCT06825624